Your browser doesn't support javascript.
Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men.
Le Bert, Nina; Chia, Wan Ni; Wan, Wei Yee; Teo, Alvin Kuo Jing; Chong, Samuel Zeng-Rong; Tan, Nicole; Tan, Doreen Soek Chin; Chia, Adeline; Tan, Iain Beehuat; Kunasegaran, Kamini; Chua, Qin Xuan; Abdad, Mohammad Yazid; Ng, Aven Shan Hua; Vasoo, Shawn; Ang, Julian Xiao-Li; Lee, Mao Sheng; Sun, Louisa; Fang, Jinyan; Zhu, Feng; Cook, Alex R; Aw, Tar Choon; Huang, Jingxiang; Tam, Clarence; Lee, Fong Sin; Clapham, Hannah; Goh, Enan Jun-Kang; Peou, Monica Socheata Suor; Tan, Shiow Pin; Ong, Siew Kim; Wang, Lin-Fa; Bertoletti, Antonio; Hsu, Li Yang; Ong, Biauw Chi.
  • Le Bert N; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Chia WN; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Wan WY; Department of Microbiology, Singapore General Hospital, Singapore, Singapore.
  • Teo AKJ; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Chong SZ; Sengkang General Hospital, Singapore, Singapore.
  • Tan N; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Tan DSC; Sengkang General Hospital, Singapore, Singapore.
  • Chia A; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Tan IB; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Kunasegaran K; National Cancer Centre, Singapore, Singapore.
  • Chua QX; Genome Institute of Singapore, Singapore, Singapore.
  • Abdad MY; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Ng ASH; Sengkang General Hospital, Singapore, Singapore.
  • Vasoo S; National Centre for Infectious Diseases, Singapore, Singapore.
  • Ang JX; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK.
  • Lee MS; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Thailand.
  • Sun L; Sengkang General Hospital, Singapore, Singapore.
  • Fang J; National Centre for Infectious Diseases, Singapore, Singapore.
  • Zhu F; Sengkang General Hospital, Singapore, Singapore.
  • Cook AR; Sengkang General Hospital, Singapore, Singapore.
  • Aw TC; Alexandra Hospital, Singapore, Singapore.
  • Huang J; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Tam C; Program in Emerging Infectious Diseases, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Lee FS; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Clapham H; Sengkang General Hospital, Singapore, Singapore.
  • Goh EJ; Sengkang General Hospital, Singapore, Singapore.
  • Peou MSS; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Tan SP; Sengkang General Hospital, Singapore, Singapore.
  • Ong SK; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Wang LF; Sengkang General Hospital, Singapore, Singapore.
  • Bertoletti A; Sengkang General Hospital, Singapore, Singapore.
  • Hsu LY; Sengkang General Hospital, Singapore, Singapore.
  • Ong BC; Sengkang General Hospital, Singapore, Singapore.
Emerg Microbes Infect ; 10(1): 2141-2150, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1532382
ABSTRACT

BACKGROUND:

We studied humoral and cellular responses against SARS-CoV-2 longitudinally in a homogeneous population of healthy young/middle-aged men of South Asian ethnicity with mild COVID-19.

METHODS:

In total, we recruited 994 men (median age 34 years) post-COVID-19 diagnosis. Repeated cross-sectional surveys were conducted between May 2020 and January 2021 at six time points - day 28 (n = 327), day 80 (n = 202), day 105 (n = 294), day 140 (n = 172), day 180 (n = 758), and day 280 (n = 311). Three commercial assays were used to detect anti-nucleoprotein (NP) and neutralizing antibodies. T cell response specific for Spike, Membrane and NP SARS-CoV-2 proteins was tested in 85 patients at day 105, 180, and 280.

RESULTS:

All serological tests displayed different kinetics of progressive antibody reduction while the frequency of T cells specific for different structural SARS-CoV-2 proteins was stable over time. Both showed a marked heterogeneity of magnitude among the studied cohort. Comparatively, cellular responses lasted longer than humoral responses and were still detectable nine months after infection in the individuals who lost antibody detection. Correlation between T cell frequencies and all antibodies was lost over time.

CONCLUSION:

Humoral and cellular immunity against SARS-CoV-2 is induced with differing kinetics of persistence in those with mild disease. The magnitude of T cells and antibodies is highly heterogeneous in a homogeneous study population. These observations have implications for COVID-19 surveillance, vaccination strategies, and post-pandemic planning.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adult / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2021 Document Type: Article Affiliation country: 22221751.2021.1999777

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Adult / Humans / Male Language: English Journal: Emerg Microbes Infect Year: 2021 Document Type: Article Affiliation country: 22221751.2021.1999777